cs-101
Cell therapyexperimental
Clinical trial activity
5 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
4
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Aug 26, 2023 (NCT06024876)
Timeline
2020s
- Jan 1, 2023
Earliest Phase 1 Sponsor(trial)
Indications
Studied for
Mechanism of action
- CD34-positive blood stem/progenitor cellSupplementation
CD34-positive blood stem/progenitor cell supplementation
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06479616 | N/A | Jun 18, 2024 | Fudan University |
| NCT06291961 | Phase 1 | Apr 18, 2024 | Government of China |
| NCT06328764 | Early Phase 1 (Phase 1) | Mar 19, 2024 | Government of China, Hacettepe University |
| NCT06065189 | Early Phase 1 (Phase 1) | Nov 7, 2023 | Fudan University, Government of China |
| NCT06024876 | Early Phase 1 (Phase 1) | Aug 26, 2023 | Government of China, Hacettepe University |
Showing 5 of 5 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Government of China | Government | 4 | 3 | 1 | 2023 |
| Fudan University | Academic/Hospital | 2 | 2 | 2 | 2023 |
| Hacettepe University | Academic/Hospital | 2 | 0 | 1 | 2023 |
3 organizations
Page 1 / 1